MD FACP - InVivo Therapeutics Consultant
| NVIVDelisted Stock | USD 1.38 0.07 5.34% |
Insider
MD FACP is Consultant of InVivo Therapeutics Holdings
| Age | 71 |
| Phone | 617 863 5500 |
| Web | https://www.invivotherapeutics.com |
InVivo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5371) % which means that it has lost $0.5371 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9811) %, meaning that it created substantial loss on money invested by shareholders. InVivo Therapeutics' management efficiency ratios could be used to measure how well InVivo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.InVivo Therapeutics Holdings currently holds 949 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. InVivo Therapeutics has a current ratio of 5.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about InVivo Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Chester III | Revelation Biosciences | 44 | |
| Nicole White | Assembly Biosciences | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Ramtin MD | RenovoRx | 58 | |
| James Brady | Spero Therapeutics | N/A | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| CPA CPA | NextCure | 61 | |
| MBA BS | CytomX Therapeutics | 45 | |
| AO FRACP | Assembly Biosciences | 65 | |
| MD FACC | Longeveron LLC | 61 | |
| Ronald CPA | RenovoRx | N/A | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Angela MD | Spero Therapeutics | N/A | |
| Deborah Knobelman | Senti Biosciences | 50 | |
Management Performance
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 |
InVivo Therapeutics Leadership Team
Elected by the shareholders, the InVivo Therapeutics' board of directors comprises two types of representatives: InVivo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InVivo. The board's role is to monitor InVivo Therapeutics' management team and ensure that shareholders' interests are well served. InVivo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InVivo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jerome Gangitano, VP Operations | ||
| Joseph MD, CoFounder | ||
| Richard Christopher, CFO, Treasurer | ||
| Dr Langer, CoFounder Board | ||
| MD FACP, Consultant | ||
| Heather JD, Chief Counsel | ||
| Richard MD, CEO and Presidentident | ||
| Richard Toselli, Chief Medical Officer | ||
| Joseph Vacanti, CoFounder |
InVivo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InVivo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | (7.59 M) | |||
| Shares Outstanding | 3.11 M | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 3.44 % | |||
| Number Of Shares Shorted | 17.63 K | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.1 X | |||
| EBITDA | (9.8 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |